ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/09/26	USD 0.000100	-0.99%	230
22/09/26	USD 0.000101	+1.00%	304
21/09/26	USD 0.000100	+9,900.00%	400
18/09/26	USD 0.000001	0.00%	1,763
17/09/26	USD 0.000001	-99.00%	3,170

Delayed Quote OTC Markets

More quotes

Delayed OTC Markets 12:53:03 24/09/26 am AEST			5-day change	1st Jan Change
0.000100 ^USD	-0.99%		+9,900.00%	-

21/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.6M 3.38M 3.09M 5.78M 393M 5.82M 40.64M 15.76M 200M 15.4M 15.06M 649M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.14M -1.07M -977K -1.83M -124M -1.84M -12.84M -4.98M -63.28M -4.87M -4.76M -205M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

21/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/04/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
14/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news: ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Price Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
01/04/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.4
5 years	0		3.27
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/4/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/2/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/2/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	-0.99%	+9,900.00%	0.00%	-99.83%	11.83K
WUXI APPTEC CO., LTD.	+0.06%	+7.20%	+54.04%	+111.13%	74.27B
ARGENX SE	-2.29%	-1.51%	+33.30%	+75.15%	61.21B
WUXI BIOLOGICS (CAYMAN) INC.	+0.28%	+7.27%	+31.74%	+23.80%	27.55B
INSMED INCORPORATED	-2.21%	-3.52%	-18.65%	+358.77%	26.38B
BIONTECH SE	-1.95%	+3.37%	+0.80%	-3.94%	25.34B
GENMAB A/S	+0.57%	+3.66%	+25.59%	-9.08%	20.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.47%	+4.46%	-8.09%	+513.33%	14.94B
PHARMAESSENTIA CORPORATION	+1.29%	-2.49%	+163.31%	+333.06%	15.17B
EXELIXIS, INC.	-2.75%	-0.32%	+42.18%	+159.28%	14.41B
Average	-0.95%	+2.98%	+32.42%	+146.16%	28.01B
Weighted average by Cap.	-0.95%	+3.08%	+35.53%	+134.60%

	2021	2022
Net sales	-	19.64M 17.24M 16.2M 14.81M 27.68M 1.88B 27.88M 195M 75.44M 959M 73.74M 72.13M 3.11B
Net income	-58.38M -51.24M -48.16M -44.03M -82.28M -5.59B -82.9M -579M -224M -2.85B -219M -214M -9.24B	-29.88M -26.22M -24.65M -22.54M -42.12M -2.86B -42.43M -296M -115M -1.46B -112M -110M -4.73B
Net Debt	-28.08M -24.64M -23.16M -21.18M -39.57M -2.69B -39.87M -278M -108M -1.37B -105M -103M -4.45B	-5.4M -4.74M -4.45M -4.07M -7.61M -517M -7.66M -53.48M -20.73M -264M -20.27M -19.82M -855M